Sample banner



Nahki Kitamura, MBA

Mr. Kitamura is currently serving as Chief Financial Officer for Miraca Holdings. He started at Miraca Holdings in 2011 as General Manager in charge of corporate strategy, and before that he held a variety of manager positions with Sony Corporation and its subsidiaries including General Manager, Corporate Planning at So-net Corp (Sony's Internet business unit in Japan), Executive Vice President at Gamepot (So-net's Gaming business unit), and Manager positions at Sony Corporation of America and Sony Electronics (Singapore), where he stationed in New York City and Singapore.

He received an MBA from MIT Sloan School of Management, and BA in Economics from Keio University.

Kengo Takishima, MBA, MA
President and CEO

Kengo Takishima is currently serving as President & CEO for Baylor Genetics. He leads the newly formed organization to leverage and expand its high-quality reputation and innovative genetic and genomic testing services. Mr. Takishima is also serving as General Manager of Miraca Holdings, in charge of Global Clinical Laboratory Testing Business, and is a member of the Board of Directors of Miraca Life Sciences. Mr. Takishima joined Miraca Holdings in 2013 and led M&A activities and strategy development as General Manager of Corporate Strategy. Before joining Miraca, Mr. Takishima served as Senior Manager at GE Capital, responsible for sales and marketing. During his tenure, he completed GE’s Experienced Commercial Leadership Program(ECLP). Prior to GE, Mr. Takishima served as Executive Officer at Kaleido Holdings, Inc.(Japanese Private Equity Fund) and led a number of investment projects as a head of an investment team. Mr. Takishima started his career at Dai-ichi Kangyo Bank, (currently Mizuho Bank) , one of the largest Japanese commercial banks, and held several positions in Sales, LBO finance, and M&A. Mr. Takishima holds an MBA from IE business school in Madrid, Spain and an MA degree in International Relations from the Fletcher Schools of Law and Diplomacy in Tufts University.

Shashikant Kulkarni, MS (Medicine), PhD, FACMG
Chief Scientific Officer

Shashikant Kulkarni, M.S (Medicine), Ph.D., FACMG is a Chief Scientific Officer (CSO) and senior Vice President (Operations) in Baylor Genetics. He is also the Vice Chairman for Research and a Professor in the department of Molecular and Human Genetics at Baylor College of Medicine.

He trained at Harvard Medical School, Imperial College at London, UK and at AIIMS, India. He is an ABMGG Board-certified medical geneticist.

In his role, Dr. Kulkarni is responsible for building a dedicated research and development team that will help translate research findings to novel clinical tests and to use human genomic data as the starting point for identifying new therapies for both constitutional and somatic disorders. He is responsible for all medical and scientific affairs activities serving as the company liaison to physician, medical, genetics and research industry groups. As the senior vice president of operations, he also oversees all aspects of laboratory operations for the laboratory.

Previously, he was a Professor in the departments of Pathology & Immunology, Pediatrics and Genetics at Washington University School of Medicine in St. Louis. He was also the Director of Cytogenomics and Molecular Pathology since 2006. In his role, Dr. Kulkarni lead one of the most modern CLIA certified and CAP accredited state-of-art full-service cytogenomics and molecular pathology laboratories in the country, currently staffed by over 150 board certified pathologists, clinical genomocists, clinical bioinformaticists and certified genetic technologists.

Dr. Kulkarni’s major research focus is in cancer genomics, specifically clinical application of next-generation sequencing to characterize cancer genomes, transcriptomes and epigenomes to drive precision genomic medicine. Dr. Kulkarni is leading efforts to defining standards for next generation sequencing in clinical diagnostics through his collaboration with the Centers for Disease Control and Prevention through the Clinical Next-Generation-Sequencing Quality Standards National Working Group, Food and Drug administration (FDA) and as a co-chairman of Clinical Laboratory Standards Institute (CLSI) for microarray-based clinical genomic diagnostics. He served on the Scientific Advisory Board of NIH Institute – National Institute of General Medical Science’s Coriell Institute, Bina Technologies, Swift Biosciences, Roche Diagnostics, Cancer Genomics Program at Princess Margaret Hospital-Toronto, Horizon Discovery and Transgenomics.

Dr. Kulkarni is considered an expert and key opinion leader in the field of Clinical Genomics and Next Generation Sequencing technology and he has given numerous invited presentations both nationally and internationally. He is on the editorial board of several peer-reviewed journals and is the editor-in-chief of Cancer Genetics journal and has co-edited a book “Clinical Genomics-A guide to clinical next-generation sequencing”.

Dr. Kulkarni is frequently featured in news media for his thoughts and opinions in key publications such as ABC news, CAP today, Nature Medicine, Nature Biotechnology to name a few. He has published extensively in peer-reviewed articles in journals such as Cell, Cell Systems, Nature, Nature Genetics, Nature Biotechnology, Journal of American Medical Association (JAMA) and New England Journal of Medicine (NEJM).

Beyond the clinical and research interests Dr. Kulkarni is committed to training next-generation clinical genomics experts by serving as the program director of the ABMGG accredited Clinical Genomics training program at Washington University School of Medicine and trains residents and fellows in clinical genomics.

One of the major bottlenecks facing the clinical implementation of NGS is the lack of clinical grade knowledge base to interpret sequence variants. With his role as the co-chairman of Somatic Cancer Workgroup in ClinGen, Dr Kulkarni is enthusiastically involved and is funded by the multi-institutional, National Institutes of Health (NIH) supported $25 million ClinGen grant awarded to develop authoritative information on the millions of genomic variants relevant to human disease and the hundreds that are expected to be useful for clinical practice.

Christine Eng, MD
Chief Quality Officer, Chief Medical Officer

Christine M. Eng, M.D. received her Bachelors degree from Yale University and Doctor of Medicine from Tulane University School of Medicine. She is board-certified by the American Board of Pediatrics and the American Board of Medical Genetics. She was on the faculty of the Department of Human Genetics at Mount Sinai School of Medicine from 2001-2010 when she relocated to Baylor College of Medicine, Houston, Texas where she is now Professor of Molecular and Human Genetics and Senior Director and Medical Director of the Baylor DNA Diagnostic Laboratory. She is also a medical geneticist and clinical researcher and expert in lysosomal storage disorders and oversees the Storage Disorders program at Texas Children’s Hospital. She serves on numerous national committees including the medical advisory boards of the National Tay-Sachs and Allied Diseases Foundation and the Fabry Support and Information Group and on the Steering Committee of the Lysosomal Disease Network.

H. Rey Stroube IV, CPA
Chief Financial Officer, Senior Vice President of Finance and Accounting

Mr. Stroube is currently servings as Chief Financial Officer for Baylor Genetics. He brings more than 25 years of finance and accounting experience to the Baylor Genetics team. Rey is responsible for all aspects of finance, treasury, and accounting for Baylor Genetics.

Previously, Rey served as the CFO of Companion Dx Reference Lab, an integrated genomics lab. He also served as an investment banker with Growth Capital Partners and The GulfStar Group, serving the middle market in all aspects of transaction management including evaluating, structuring and executing private placements of capital, mergers and acquisitions, and corporate restructuring transactions. Mr. Stroube began his career at Arthur Andersen with a focus on providing accounting and advisory services to middle-market companies.

Rey graduated from Washington and Lee University with a bachelor’s degree in accounting with special attainments in commerce. He is a licensed CPA in the State of Texas.

Sean Kim, CPA, MBA
Chief Compliance Officer, Senior Vice President of Strategic Initiatives and Human Resources

Sean Kim joins Baylor Genetics after a lengthy career at Baylor College of Medicine. He began his career with Baylor College of Medicine in 2002 and has held various healthcare administration and management roles. Since 2008, he has been responsible for managing and overseeing laboratory business operations at the Medical Genetics Laboratories. Sean earned a bachelor’s degree in economics, psychology, and managerial studies and a master’s degree in business administration from Rice University. He is also a Texas Certified Public Accountant.

Irina Sinitsyna, MS, MB (ASCP)
Associate Vice President of Laboratory Operations

Irina Sinitsyna oversees the laboratory production team with the focus on efficiency and automation. She brings over 20 years of commercial laboratory experience to the Baylor Genetics team. Previously she had various technical and administrative positions at Sequenom, LabCorp and ARUP laboratories in genetics and oncology areas.

Irina holds Master Degree in Chemistry from Lomonosov State University and has MB (ASCP) certification.

Alan Pourpak, PhD, MBA
Associate Vice President of Product Management and R&D

Alan Pourpak has been with Baylor Genetics since its inception and, prior to that, was with Baylor College of Medicine’s Medical Genetics Laboratories. He received his Bachelor’s degree at the University of Utah, his MBA at Christian Brothers University, and his PhD in Pharmacology and Toxicology at the University of Arizona. His research studies included identifying small molecule inhibitors to proteins involved in specific subtypes of childhood leukemias at St. Jude Children’s Research Hospital. His scientific background, along with his experience in a clinical genetics laboratory, provide him with a unique perspective on the importance of a well-developed product paired with a strong message that solidifies the differentiating and comprehensive attributes of the product.

Vito Oliveri, MBA, MS
Associate Vice President of Business Operations and Quality

Vito is currently serving as Associate Vice President of Business Operations and Quality. Vito received his Master of Science degree in Biology and later an MBA from Hofstra University in New York. He started his career in academia then transitioned to the pharmaceutical industry working for a large multinational pharmaceutical company. During his time at the pharmaceutical company, Vito initially began his career as Analytical Chemist and then moved over to Operations/Project Management. He was responsible for overseeing global logistics and import/export channels with multiple foreign partners dealing with highly valuable to highly sensitive material. Vito then continued his operational career at Baylor College of Medicine, where he helped oversee laboratory Business Operations at the Medical Genetics Laboratories (MGL). During his tenure at the MGL, Vito held various roles and functions of increasing responsibilities. In his current role, he is responsible for all aspect of Business Operations, Quality, Billing, and total Customer Experience.